DexTech Medical AB Interim report 1 July – 30 September 2026
First quarter summary, July – September 2026
· Net sales amounted to MSEK 0.0 (0.0)
· Operating profit amounted to MSEK -1.5 (-1.3)
· Earnings per share* SEK -0.08 (-0.07)
· Cash and cash equivalents at the end of the period amounted to MSEK 7.7 (8.6)
Clinical highlights
· During the quarter, the follow-up of patients in the phase I/IIa study with OsteoDex in multiple myeloma continued after the treatment part was completed in February 2026.
· After the end of the quarter, in October 2026, the clinical study report (CSR) was completed, confirming previously